Market Eyes LiveBecton, Dickinson and Co. (BDX) Stock Rating & Analysis
MELANY's data-driven read on Becton, Dickinson and Co. · Surgical & Medical Instruments & Apparatus.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) is the legacy medical surgical unit selling catheters, syringes, and infection prevention products. Connected care (24%) includes the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) makes prefillable syringes and autoinjectors. Interventional (29%) covers surgery, peripheral vascular, and urology. More than 60% of revenue comes from the US.
Why BDX scores 63/100
MELANY scores Becton, Dickinson and Co. 63/100 by weighing eight factors. Here is how BDX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 14.1x, earnings growth accelerating
- PEG ratio 1.11 (< 1 = undervalued)
- FCF yield 8.8%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 46%
Direction and relative strength of the recent share-price trend.
- Price +17.2% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for BDX
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Becton, Dickinson and Co. sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds BDX's momentum and catalyst factors above.
Tracking BDX
Becton, Dickinson and Co. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add BDX to your watchlist and get alerted the moment the rating changes.
How MELANY rates BDX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Becton, Dickinson and Co.'s 63/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BDX
Is Becton, Dickinson and Co. (BDX) a buy?
As of 2026-08-20, MELANY rated Becton, Dickinson and Co. Hold with a composite score of 63/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Becton, Dickinson and Co.'s MELANY score?
Becton, Dickinson and Co. (BDX) has a MELANY composite score of 63/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the BDX stock rating calculated?
MELANY scores BDX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Becton, Dickinson and Co. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Becton, Dickinson and Co. (BDX) Hold with a composite of 63/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BDX stock price forecast?
MELANY does not publish price targets or forecasts for BDX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 63/100 across eight factors for Becton, Dickinson and Co., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BDX stock overvalued or undervalued?
MELANY's valuation factor currently reads 72/100 for Becton, Dickinson and Co., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BDX's read.
What price should I buy BDX at?
MELANY is not flagging a fresh entry for BDX at its current Hold rating, so there is no entry zone to publish right now. Watchlisting BDX in the free app gets you alerted the moment that changes.
What are the risks of buying BDX stock?
The top risks MELANY currently flags for Becton, Dickinson and Co.: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Becton, Dickinson and Co. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 51/100 for Becton, Dickinson and Co., and earnings track record, at 68/100. The 63/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BDX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 74/100 for BDX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BDX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BDX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
BDX's live rating and alerts are free either way. The app is our flagship.